AURA3: Osimertinib versus Platinum-Based Chemotherapy in EGFR T790M-Positive Advanced NSCLC
Source: View publication →
The AURA3 trial demonstrated that third-generation EGFR inhibitor osimertinib significantly improves progression-free survival compared to platinum-pemetrexed chemotherapy in patients with T790M-positive non-small cell lung cancer who progressed on prior EGFR-TKI therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
AURA3 established osimertinib as the standard of care for patients with advanced EGFR-mutated NSCLC who develop the T790M resistance mutation after initial EGFR-TKI therapy, replacing platinum-based chemotherapy in this setting.
Historical Context
Before AURA3, acquired resistance to first-generation EGFR-TKIs was a major clinical challenge, with the T790M mutation accounting for approximately 60% of such resistance cases. The trial served as a confirmatory Phase III study to support the accelerated approval of osimertinib, moving the paradigm away from cytotoxic chemotherapy for patients with identifiable T790M mutations.
Guided Discussion
High-yield insights from every perspective
Explain the biochemical mechanism by which the T790M mutation confers resistance to first-generation EGFR inhibitors like erlotinib and how osimertinib overcomes this.
Key Response
The T790M 'gatekeeper' mutation replaces a threonine residue with a bulkier methionine in the ATP-binding pocket of the EGFR kinase domain, sterically hindering the binding of first-generation reversible TKIs. Osimertinib is a third-generation, irreversible inhibitor that forms a covalent bond with the Cys797 residue, allowing it to maintain high affinity for the receptor even in the presence of the T790M mutation.
A patient with EGFR-mutated NSCLC progresses on gefitinib. According to the paradigm established by AURA3, what is the necessary diagnostic workflow before switching to osimertinib?
Key Response
The patient must undergo molecular testing specifically for the T790M resistance mutation. This is typically done via a 'plasma-first' approach using liquid biopsy (ctDNA). If the liquid biopsy is negative, a tissue re-biopsy is required to rule out a false negative, as AURA3 demonstrated that osimertinib's superior efficacy over chemotherapy is contingent upon T790M-positive status.
Discuss the clinical significance of osimertinib's CNS penetration as demonstrated in the AURA3 trial compared to the platinum-pemetrexed control arm.
Key Response
In patients with stable CNS metastases at baseline, AURA3 showed that osimertinib significantly prolonged CNS progression-free survival (11.7 months vs 5.6 months). This is due to osimertinib's superior blood-brain barrier penetration compared to chemotherapy and earlier TKIs, making it a preferred agent for preventing or treating intracranial progression in the T790M+ setting.
Given the results of the subsequent FLAURA trial, how has the practical application of the AURA3 data shifted in current oncology practice for newly diagnosed EGFR-mutant NSCLC?
Key Response
While AURA3 established osimertinib as the second-line standard for T790M+ patients, the FLAURA trial demonstrated its superiority in the first-line setting regardless of T790M status. Consequently, AURA3 remains relevant primarily for 'legacy' patients who were started on 1st/2nd generation TKIs, though most new patients now receive osimertinib upfront, rendering the T790M resistance pathway less common in later lines.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
AURA3 permitted crossover from the chemotherapy arm to the osimertinib arm. Evaluate how this design affects the analysis of Overall Survival (OS) and describe a statistical approach to mitigate this confounding variable.
Key Response
Crossover frequently leads to an underestimation of the survival benefit (Type II error) in the experimental arm because control-group patients receive the active drug after progression. To adjust for this, researchers often utilize the Rank-Preserving Structural Failure Time (RPSFT) model or Inverse Probability of Censoring Weighting (IPCW) to estimate a crossover-adjusted hazard ratio for OS.
In AURA3, the T790M status was determined by local or central testing using various assays. What concerns might a reviewer raise regarding the lack of a single companion diagnostic for the primary analysis of PFS?
Key Response
The use of heterogeneous testing methods (tissue vs. plasma, varying sensitivity of NGS vs. PCR) can introduce selection bias and variability in the study population. A reviewer would demand a subgroup analysis comparing outcomes between patients identified via liquid biopsy versus tissue biopsy to ensure the treatment effect is robust across different diagnostic thresholds.
How does AURA3 influence the NCCN and ASCO recommendations regarding the management of EGFR-mutant NSCLC patients who progress without a detectable T790M mutation?
Key Response
AURA3 specifically demonstrated benefit in T790M+ patients; therefore, guidelines (e.g., NCCN Category 1) only recommend osimertinib in the second line for T790M+ disease. If a patient is T790M-negative after both plasma and tissue testing, guidelines recommend platinum-based doublet chemotherapy (the control arm of AURA3), as there is no evidence that osimertinib outperforms chemotherapy in T790M-negative resistance.
Clinical Landscape
Noteworthy Related Trials
IPASS Trial
Tested
Gefitinib
Population
Advanced NSCLC in never- or light-smokers
Comparator
Carboplatin plus paclitaxel
Endpoint
Progression-free survival
LUX-Lung 3 Trial
Tested
Afatinib
Population
EGFR mutation-positive advanced NSCLC
Comparator
Cisplatin plus pemetrexed
Endpoint
Progression-free survival
FLAURA Trial
Tested
Osimertinib
Population
Untreated EGFR-mutated advanced NSCLC
Comparator
Erlotinib or Gefitinib
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis